Vitamins b and c strong iv injection
- Drugs List
- Therapeutic Indications
- Dosage
- Administration
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Pair of ampoules containing:
No1 (5ml ampoule): thiamine hydrochloride 250mg, riboflavin 4mg and pyridoxine hydrochloride 50mg
No2 (5ml ampoule): ascorbic acid 500mg, nicotinamide 160mg and glucose (as monohydrate) 1000mg
Drugs List
Therapeutic Indications
Uses
Alcoholism (adjunctive treatment)
Debility - severe (after major surgery or disease)
Haemodialysis - maintenance of vitamins B and C levels
Vitamin B deficiency
Vitamin C deficiency
Wernickes encephalopathy
Rapid correction of severe depletion or malabsorption of vitamins B and C (e.g. in alcoholism, where a severe depletion of thiamine can lead to Wernicke's encephalopathy, after acute infections, post operatively and in psychiatric states).
Maintenance of adequate levels of vitamins B and C in patients on chronic intermittent haemodialysis.
Dosage
This preparation is also available as an Intramuscular Strong Injection. Therefore ensure that the labels of the ampoule are for the desired route before administration.
Adults
Rapid correction of severe depletion or malabsorption of vitamins B and C
10ml solution from Ampoule Number 1 plus 10ml solution from Ampoule Number 2 or 15ml solution from Ampoule Number 1 plus 15ml solution from Ampoule Number 2 every 8 hours by intravenous infusion over 30 minutes.
Psychosis following narcosis or electroconvulsive therapy (ECT); Toxicity from acute infections
5ml Ampoule Number 1 plus 5ml Ampoule Number 2 twice daily up to 7 days by intravenous infusion over 30 minutes.
Haemodialysis
5ml Ampoule Number 1 plus 5ml Ampoule Number 2 once every two weeks, given at the end of dialysis by intravenous infusion over 30 minutes.
The following alternative dosing schedule may be suitable:
Treatment of Wernicke's encephalopathy
2 to 3 pairs three times a day for 3 to 5 days, followed by 1 pair once daily for 3 to 5 days, or for as long improvement continues.
Children
Children aged 14 to 18 years: See Dosage; Adult
Children aged 10 to 14 years: One half to two thirds of the adult dose.
Children aged 6 to 10 years: One third of the adult dose.
Children under 6 years: One quarter of the adult dose.
Administration
For intravenous administration only by drip infusion over 30 minutes.
Contraindications
None known
Precautions and Warnings
Restricted sodium intake
Breastfeeding
Pregnancy
Contains more than 1 mmol (23 mg) sodium per dose
Administer by IV infusion over 30 minutes
Do not use if any signs of precipitate or particulate matter apparent
Must be diluted before use
Resuscitation facilities must be immediately available
Use only when parenteral treatment is essential
For intravenous administration only. Care should be taken to ensure that the route of administration is the desired route before administering the product to the patient.
Pregnancy and Lactation
Pregnancy
Use vitamins B and C strong intravenous injection with caution during pregnancy.
The manufacturer advises caution if vitamins B and C strong intravenous injection is used during pregnancy. At the time of writing there is limited published information regarding the use of vitamins B and C strong intravenous injection during pregnancy. Potential risks are unknown.
Lactation
Use vitamins B and C strong intravenous injection with caution during breastfeeding.
The manufacturer advises caution if vitamins B and C strong intravenous injection is used when breastfeeding. The presence of the vitamin B and C strong intravenous injection in human breast milk and effects on exposed infants are unknown.
Side Effects
Anaphylaxis
Hypersensitivity reactions
Hypotension
Local pain (injection site)
Paraesthesia
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: January 2020
Reference Sources
Summary of Product Characteristics: Pabrinex Intravenous High Potency Injection. Kyowa Kirin Ltd. Revised May 2018.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 17 January 2020
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.